LEADER 04133nam  22005535  450 
001 9910299363103321
005 20200704090548.0
010   $a3-658-22074-0
024 7 $a10.1007/978-3-658-22074-7
035   $a(CKB)4100000004244107
035   $a(DE-He213)978-3-658-22074-7
035   $a(MiAaPQ)EBC5394410
035   $a(EXLCZ)994100000004244107
100   $a20180514d2018      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aLaw and Economics of Personalized Medicine $eInstitutional Levers to Foster the Translation of Personalized Medicine /$fby Karin Bosshard
205   $a1st ed. 2018.
210  1$aWiesbaden :$cSpringer Fachmedien Wiesbaden :$cImprint: Springer Gabler,$d2018.
215   $a1 online resource (XXXVI, 411 p. 41 illus., 7 illus. in color.) 
225 1 $aGesundheitsmanagement und Gesundheitsökonomik,$x2523-7667
311   $a3-658-22073-2 
327   $aOverview of terminologies used in the context of personalized medicine -- Description of personalized medicine?s impact on the healthcare landscape -- Identification and analysis of the institutional barriers to the translation of personalized medicine into clinical practice -- Analysis of institutional barriers to the translation of personalized medicine in Switzerland -- Identification and evaluation of institutional levers to foster the translation of personalized medicine into Swiss clinical practice.
330   $aThe book adds to the discussion about strategic approaches towards the translation of personalized medicine into clinical practice. It stresses the importance of non-science related, institutional barriers. A Law and Economics perspective is applied in order to examine the incentives induced by the barriers. An applied part identifies and evaluates policy levers to foster the translation of personalized medicine into Swiss clinical practice. The content ? Overview of terminologies used in the context of personalized medicine ? Description of personalized medicine?s impact on the healthcare landscape ? Identification and analysis of the institutional barriers to the translation of personalized medicine into clinical practice ? Analysis of institutional barriers to the translation of personalized medicine in Switzerland ? Identification and evaluation of institutional levers to foster the translation of personalized medicine into Swiss clinical practice Target groups ? Social scientists with limited knowledge of personalized medicine, Law and Economics scholars, health economists ? Practitioners in pharmaceutical, diagnostics and health insurance companies, healthcare policy makers and Swiss lawyers The author Dr. Karin Bosshard wrote this book during her time with a globally leading management consultancy where she was working as a strategy consultant. The author is currently working at an international pharmaceutical and diagnostics company and is a lecturer at the University of St. Gallen.
410  0$aGesundheitsmanagement und Gesundheitsökonomik,$x2523-7667
606   $aLaw and economics
606   $aEvolutionary economics
606   $aHealth economics
606   $aLaw and Economics$3https://scigraph.springernature.com/ontologies/product-market-codes/W39000
606   $aInstitutional/Evolutionary Economics$3https://scigraph.springernature.com/ontologies/product-market-codes/W53010
606   $aHealth Economics$3https://scigraph.springernature.com/ontologies/product-market-codes/W35000
615  0$aLaw and economics.
615  0$aEvolutionary economics.
615  0$aHealth economics.
615 14$aLaw and Economics.
615 24$aInstitutional/Evolutionary Economics.
615 24$aHealth Economics.
676   $a615.7
700   $aBosshard$b Karin$4aut$4http://id.loc.gov/vocabulary/relators/aut$01065312
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910299363103321
996   $aLaw and Economics of Personalized Medicine$92544456
997   $aUNINA